Muhammad Husnain, MD, University of Arizona, Arizona Cancer Center, Tucson, AZ, discusses the impact of pre-transplant molecular measurable residual disease (MMRD) and European Leukemianet (ELN) genetic classification in clinical outcomes for acute myeloid leukemia (AML) patients undergoing allogeneic stem cell transplantation (alloHCT). This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.